Why rising GLP-1 costs aren’t going away and what to do about it. Read more in the HDMS case study.
HDMS Case Study: Three Cost Containment Strategies for GLP-1 Drugs
Latest Posts
Partner News
Novo Nordisk: The Management of Obesity for Appropriate Individuals: Questions, Answers and Resources
Recently, there has been significant interest in anti-obesity medications (AOMs) from the general public, employers, ...
Read More
Blog
Financial Wellbeing: The Next Frontier in Employee Benefits
Barbara Thompson, Director & Karine Desruisseaux, Sr Program Manager at Silicon Valley Employers Forum In ...
Read More
Partner News
Grayce: New 2024 Employee Leave Trends Report
The number of employees taking leave, and the cost to employers, is increasing by 20-40% ...
Read More